

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Brii Biosciences Limited**  
**腾盛博药生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2137)**

**VOLUNTARY ANNOUNCEMENT**  
**BUSINESS UPDATE**

This announcement is made by the board of directors (the “**Board**”) of Brii Biosciences Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce that TSB Therapeutics (Beijing) Co., Ltd. (“**TSB Therapeutics**”), a joint venture majority-owned by the Company, is partnering with Sinopharm Holding Co., Ltd. (“**Sinopharm Holding**”) to advance stockpiling, channel distribution and regional access of the Company’s long-acting neutralizing monoclonal antibody therapy, the amubarvimab/romlusevimab combination, to contribute to the COVID-19 pandemic prevention and control efforts in China.

On December 8, 2021, the National Medical Products Administration of China approved the amubarvimab/romlusevimab combination (previously known as BRII-196/BRII-198 combination) for the treatment in adults and pediatric patients (age 12-17 weighing at least 40 kg) with mild and normal type of COVID-19 at high risk for progression to severe disease, including hospitalization or death. The indication of pediatric patients (age 12-17 weighing at least 40 kg) is under a conditional approval. On March 15, 2022, the National Health Commission of China added the amubarvimab/romlusevimab combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition) (the “**Guidelines**”) for the treatment of COVID-19.

“The pandemic continues to affect the health of communities worldwide and most recently aggressively impacting China. As a biotechnology company with the mission of tackling the major public health challenges, we are duty-bound to support the pandemic prevention and control,” said Mr. Yongqing Luo, the President and General Manager of Greater China of the Company and the Chief Executive Officer of TSB Therapeutics. “We are pleased to partner with Sinopharm Holding, a leading state-owned pharmaceutical distribution company in China. We believe that with their advanced distribution channels and strong channel management ability, we are able to accelerate the accessibility of our combination therapy to help more COVID-19 patients in China.”

“It has been the third year since the outbreak of the pandemic. We have been hoping that a treatment will be available soon besides vaccines,” said Mr. Yong Liu, the President and Deputy Secretary of Party Committee of Sinopharm Holding. “As a service provider in the central pharmaceutical reserve, Sinopharm Holding must always shoulder the important responsibility of ensuring the supply of drugs for the country and the people. The strategic cooperation with the Company is an essential strategic partnership between commercial and industrial enterprises in the field of public health. We will leverage our strong distribution network and provincial subsidiaries nationwide and global procurement and supply chain service centers to provide a comprehensive cooperation scheme including drug stockpiling, commercialization and innovation services, thereby improving the accessibility of the Company’s self-developed COVID-19 therapeutic drugs and benefiting more patients.”

On March 21, 2022, the National Healthcare Security Administration of China issued a notice to temporarily include the newly added drugs in the Guidelines into the reimbursement scope of the provincial health insurance fund. Since March 22, 2022, the Healthcare Security Administrations of various provinces and cities in China, including Hunan, Beijing, Shanghai, Zhejiang, Jiangsu, Sichuan, Shanxi, Guizhou, Liaoning and Anhui, have successively implemented the instructions of the said notice and included the amubarvimab/romlusevimab combination into the reimbursement scope of the local health insurance fund.

With the recognition of the national healthcare authorities and clinical experts for the amubarvimab/romlusevimab combination, as of March 29, 2022, TSB Therapeutics has received purchase intention and stockpiling requests from near 20 provincial Health Commissions and over 100 healthcare institutions and distribution companies. The Company is rapidly preparing for the production and supply work in order to provide the amubarvimab/romlusevimab combination therapy to patients in need as soon as possible.

**Cautionary Statement:** Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek advice from professional or financial advisers.

By order of the Board  
**Brii Biosciences Limited**  
**Dr. Zhi Hong**  
*Chairman*

Hong Kong, March 30, 2022

*As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.*